US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Primary Purpose
High Risk Myeloid Malignancies, Cord Blood Transplant
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Sponsored by

About this trial
This is an interventional treatment trial for High Risk Myeloid Malignancies
Eligibility Criteria
Inclusion Criteria:
Acute Myeloid Leukemia
- Chemo-refractory relapse (MRD+)
- Primary induction failure (no CR or CRi after >= 2 courses of intensive induction therapy): < 30% blasts in evaluable marrow.
- Relapse after previous allogeneic (or autologous) transplant (>4 months)
- Secondary or therapy-related MDS/AML
- Poor response to induction (5-30% blasts) or MDR+ after induction
Myelodysplastic syndrome (MDS)
- Relapse after allogeneic or autologous transplant (>4 months)
- ≥10 % blasts within 30 days of start of conditioning regimen
- Poor and very poor cytogenetics abnormalities
- Chronic myelogenous leukemia: Patients who progressed to blast crisis
- Mixed Phenotype Acute Leukemia: MRD+ or relapse after previous transplant (>4 months).
- JMML (Juvenile Myelo-Monocytic Leukemia)
Availability of 2 ≥ 4/8 HLA matched CBU (allele level: A, B, C and DRB1)
- Cord to be expanded: CD34+ cell count ≥ 0.5 x 10^5/kg and TNC ≥ 1.5 x 10^7/kg (pre-cryo)
- Back up cord: Pre-freeze TNC ≥ 2 x 10^7/kg with CD34+ cells ≥ 1.5 x 10^5/kg. If a single cord does not meet this criterion 2 back up cords will be an acceptable alternative with a minimum for each of 1.5 x 10^7 TNC/kg with 1.0 x 10^5 CD34+/kg. Another acceptable HSC back up source could be a haploidentical with medical clearance prior to starting conditioning regimen.
- Lansky / Karnofsky >60%
- Bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis; AST and ALT < 3 x ULN; alkaline phosphatase < 5 x ULN
- Estimated or measured creatinine clearance ≥ 50ml/min/1.73m2
- Left ventricular ejection fraction of ≥ 40%
- FVC, FEV1 and DLCO ≥ 50% of predicted
- Signed written informed consent
- Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and mush be willing to use an effective contraceptive method while enrolled in the study.
Exclusion Criteria:
- Previous allogeneic transplantation within 4 months.
- Uncontrolled infection.
- Presence of other malignancy other than the one for which the CB transplant is being performed, with an expected survival to be less than 75% at 5 years
- Seropositive for HIV.
- Hep B and C infection with measurable viral load.
- Liver cirrhosis.
- Active CNS disease.
- Chloroma > 2cm.
- >30% blasts in marrow in evaluable marrow sample.
- Pregnancy, breastfeeding, or unwillingness to use appropriate contraception
- Participation in a trial with an investigational agent within 30days prior to entry in the study.
- Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.
Sites / Locations
- Memorial Sloan Kettering Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ECT-001-Expanded CB
Arm Description
Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI) The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus).
Outcomes
Primary Outcome Measures
Adverse events of ECT-001-CB
Incidence and severity of AEs according to the modified (for HSCT) CTCAE (v. 5.0)
Relapse
Incidence of relapse will be measured from time of transplant
Secondary Outcome Measures
Leukemia-free survival
LFS will be measured from time of transplant until disease relapse, death or last follow-up
Non-Relapse Mortality
NRM is defined as any death of any cause other than malignant relapse, occurring after the commencement of conditioning regimen that could be related to the transplantation procedure
GVHD
Incidence of acute and chronic GVHD will be measured by NIH criteria
Grade 3 Infections
Incidence and severity of infections requiring systemic therapy, e.g., invasive candidiasis, aspergillus, other invasive fungi, CMV, adenovirus, EBV, HHV-6, HSV, VZV, PCP, toxoplasmosis and mycobacterium
Hematologic engraftment
Time to neutrophil engraftment (the first day of attainment of an absolute neutrophil count ≥0.5 x 10E9/L for 3 consecutive days. Time to ANC ≥ 0.1 x 10E9/L will also be documented) and time to platelet engraftment (first day of a sustained platelet count ≥ 50 x 10E9/L with no platelet transfusion in the preceding 7 days)
Pre-engraftment/engraftment syndrome
Incidence of pre-engraftment/engraftment syndrome requiring therapy
Hospitalization events
Duration of transplant admission and number of days in hospital in 1st 100 days, and last day of fever (>38°C) prior to engraftment
Full Information
NCT ID
NCT04990323
First Posted
July 27, 2021
Last Updated
September 5, 2023
Sponsor
ExCellThera inc.
Collaborators
Memorial Sloan Kettering Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT04990323
Brief Title
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Official Title
A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult (<21year) Patients With High-Risk and Very High-Risk Myeloid Malignancies
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ExCellThera inc.
Collaborators
Memorial Sloan Kettering Cancer Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limitation, allowing for CB's important qualities as lower risk of chronic GVHD and relapse to prevail. In previous trials (NCT02668315, NCT03913026, NCT04103879, and NCT03441958), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe in adults.
UM171 expanded CB was associated with a prompt (D+17), robust (98%) and durable neutrophil recovery. Amongst patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (10%), grade 3-4 acute GVHD (13%) and moderate-severe chronic GVHD (2%) was low at 1 year post-transplant. Incidence of severe viral and bacterial infections was reduced and immunosuppression could be discontinued in 77% of patients at 1 year. Thus, PFS and GRFS were very promising, 72% and 59% at 12 months, 69% and 53% at 24 months, respectively, in particular accounting for a large proportion of very high-risk patients. By a 10-fold increase of CB accessibility, ECT-001-CB allowed access to smaller, better HLA matched CBs.
This new study seeks to test a similar strategy in a group of pediatric and young adult patients with high risk myeloid malignancies. 12 patients will be enrolled in the first stage of this 2-stage design protocol. If intervention is considered promising (<= 3 relapses in the first 12 patients), this study will open multicenter and be extended to a second stage (16 additional patients for a total accrual 28).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High Risk Myeloid Malignancies, Cord Blood Transplant
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ECT-001-Expanded CB
Arm Type
Experimental
Arm Description
Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI)
The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.
Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus).
Intervention Type
Biological
Intervention Name(s)
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Other Intervention Name(s)
Conditioning Regimen (Preferred): clofarabine:30 mg/m2/day IV x 4 days, fludarabine:10 mg/m2/day IV x 4 days, busulfan: daily for 4 days with cumm Bu target = 90mg h/L, Conditioning Regimen (Alternative): MIDI: fludarabine: 30 mg/m2/day IV x 5 days, cyclophosphamide: 50 mg/kg IV , thiotepa: 5 mg/kg/day IV x 2 days , TBI: 400 cGy, GVHD Prophylaxis: Tacrolimus/MMF
Intervention Description
Single UM171-Expanded CB transplant (CD34+: 2.5-50x10^5/kg, CD3+>1x10^6/kg)
Primary Outcome Measure Information:
Title
Adverse events of ECT-001-CB
Description
Incidence and severity of AEs according to the modified (for HSCT) CTCAE (v. 5.0)
Time Frame
100 days
Title
Relapse
Description
Incidence of relapse will be measured from time of transplant
Time Frame
1 year post-transplant
Secondary Outcome Measure Information:
Title
Leukemia-free survival
Description
LFS will be measured from time of transplant until disease relapse, death or last follow-up
Time Frame
1- and 2-year post-transplant
Title
Non-Relapse Mortality
Description
NRM is defined as any death of any cause other than malignant relapse, occurring after the commencement of conditioning regimen that could be related to the transplantation procedure
Time Frame
1 year post-transplant
Title
GVHD
Description
Incidence of acute and chronic GVHD will be measured by NIH criteria
Time Frame
1- and 2-year post-transplant
Title
Grade 3 Infections
Description
Incidence and severity of infections requiring systemic therapy, e.g., invasive candidiasis, aspergillus, other invasive fungi, CMV, adenovirus, EBV, HHV-6, HSV, VZV, PCP, toxoplasmosis and mycobacterium
Time Frame
2-year post-transplant
Title
Hematologic engraftment
Description
Time to neutrophil engraftment (the first day of attainment of an absolute neutrophil count ≥0.5 x 10E9/L for 3 consecutive days. Time to ANC ≥ 0.1 x 10E9/L will also be documented) and time to platelet engraftment (first day of a sustained platelet count ≥ 50 x 10E9/L with no platelet transfusion in the preceding 7 days)
Time Frame
42 and 100 days
Title
Pre-engraftment/engraftment syndrome
Description
Incidence of pre-engraftment/engraftment syndrome requiring therapy
Time Frame
2-year post-transplant
Title
Hospitalization events
Description
Duration of transplant admission and number of days in hospital in 1st 100 days, and last day of fever (>38°C) prior to engraftment
Time Frame
100 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
0 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute Myeloid Leukemia
Chemo-refractory relapse (MRD+)
Primary induction failure (no CR or CRi after >= 2 courses of intensive induction therapy): < 30% blasts in evaluable marrow.
Relapse after previous allogeneic (or autologous) transplant (>4 months)
Secondary or therapy-related MDS/AML
Poor response to induction (5-30% blasts) or MDR+ after induction
Myelodysplastic syndrome (MDS)
Relapse after allogeneic or autologous transplant (>4 months)
≥10 % blasts within 30 days of start of conditioning regimen
Poor and very poor cytogenetics abnormalities
Chronic myelogenous leukemia: Patients who progressed to blast crisis
Mixed Phenotype Acute Leukemia: MRD+ or relapse after previous transplant (>4 months).
JMML (Juvenile Myelo-Monocytic Leukemia)
Availability of 2 ≥ 4/8 HLA matched CBU (allele level: A, B, C and DRB1)
Cord to be expanded: CD34+ cell count ≥ 0.5 x 10^5/kg and TNC ≥ 1.5 x 10^7/kg (pre-cryo)
Back up cord: Pre-freeze TNC ≥ 2 x 10^7/kg with CD34+ cells ≥ 1.5 x 10^5/kg. If a single cord does not meet this criterion 2 back up cords will be an acceptable alternative with a minimum for each of 1.5 x 10^7 TNC/kg with 1.0 x 10^5 CD34+/kg. Another acceptable HSC back up source could be a haploidentical with medical clearance prior to starting conditioning regimen.
Lansky / Karnofsky >60%
Bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis; AST and ALT < 3 x ULN; alkaline phosphatase < 5 x ULN
Estimated or measured creatinine clearance ≥ 50ml/min/1.73m2
Left ventricular ejection fraction of ≥ 40%
FVC, FEV1 and DLCO ≥ 50% of predicted
Signed written informed consent
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and mush be willing to use an effective contraceptive method while enrolled in the study.
Exclusion Criteria:
Previous allogeneic transplantation within 4 months.
Uncontrolled infection.
Presence of other malignancy other than the one for which the CB transplant is being performed, with an expected survival to be less than 75% at 5 years
Seropositive for HIV.
Hep B and C infection with measurable viral load.
Liver cirrhosis.
Active CNS disease.
Chloroma > 2cm.
>30% blasts in marrow in evaluable marrow sample.
Pregnancy, breastfeeding, or unwillingness to use appropriate contraception
Participation in a trial with an investigational agent within 30days prior to entry in the study.
Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jaap Jan Boelens, MD, PhD
Phone
212-639-3643
Email
boelensj@mskcc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Andromachi Scaradavou, MD
Phone
212-639-3267
Email
scaradaa@mskcc.org
Facility Information:
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andromachi Scaradavou, MD
First Name & Middle Initial & Last Name & Degree
Jaap J Boelens, MD
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
We'll reach out to this number within 24 hrs